New England Journal of Medicine

News

NEJM responds to claims of bias from Justice Department

The New England Journal of Medicine (NEJM) has hit back at assertions of bias in its editorial policies from Republican activist Edward Martin Jr.

News

Eisai's full lecanemab phase 3 trial results for Alzheimer's...

Following the news of two lecanemab-related deaths reported on the eve of the C

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

New England Journal of Medicine

Editor's Picks